Pharma News
24 Aug 2025 to 30 Aug 2025
Aug 30, 2025
New medication praised as a 'revolutionary' solution for managing persistent high blood pressure.
AstraZeneca's new drug, baxdrostat, has shown promising results in trials for patients with resistant high blood pressure, reducing levels by 9-10 mmHg. The BaxHTN study involved 796 patients and revealed that nearly 40% achieved healthy blood pressure. This breakthrough could benefit up to half a billion people globally. Additionally, Novartis' Leqvio (inclisiran) was highlighted for its effectiveness in cholesterol management.
Aug 30, 2025
Impact of IRA Rx price negotiations to influence competition - BioWorld
The upcoming U.S. prescription drug price negotiations are set to impact competition significantly. The CMS will publish maximum fair prices (MFPs) for selected drugs by Nov. 30, with the first round's MFPs effective Jan. 1. Additionally, by Feb. 1, CMS will announce up to 15 drugs for negotiation for the 2028 price year, including Part B drugs.
Aug 30, 2025
The Replication of Viagra - ASIANOW - Asiaweek
Indian pharmaceutical companies Orchid Chemicals and Cipla are preparing to produce clones of Viagra, the anti-impotence drug, using sildenafil citrate. With India's patent laws allowing process patents, these companies aim to capitalize on the lucrative market, despite Pfizer's concerns over intellectual property rights. The Indian drug industry is projected to grow significantly, with exports already accounting for a third of its $2.7 billion turnover.
Aug 30, 2025
Cancer medications that have been approved will undergo re-evaluation, according to DrugsControl Media Services.
The Delhi government's Drugs Control Department has announced plans to re-test cancer medicines after 75 samples initially passed quality checks. The health department expressed dissatisfaction with the initial report, prompting further scrutiny of the medicines' quality.
Aug 30, 2025
New medication recognized as a 'breakthrough' in addressing persistently elevated blood pressure.
AstraZeneca's new drug, baxdrostat, has shown promising results in lowering blood pressure for patients resistant to existing treatments, with a significant reduction of 9-10 mmHg in trials. The BaxHTN study involved 796 patients and revealed that nearly 40% achieved healthy blood pressure levels. This breakthrough could benefit up to half a billion people globally, marking a significant advancement in hypertension treatment.
Aug 29, 2025
Alphamab Oncology Reports Interim Results for 2025 and Updates on Strategic Pipeline Developments - AInvest
Alphamab Oncology has made significant progress in 2025 with its candidates JSKN003 and KN046. JSKN003, an anti-HER2 ADC, received Breakthrough Therapy Designation in China and Orphan Drug Designation in the U.S. for various cancers. Meanwhile, KN046, a bispecific antibody, showed promising results in lung cancer but faced setbacks in pancreatic cancer trials. The company aims for global expansion and strategic partnerships to enhance its market position.
Aug 29, 2025
Eli Lilly Collaborates with JD Health to Sell Obesity and Diabetes Medications Directly to Consumers
Eli Lilly has partnered with JD Health International to sell its obesity and diabetes drugs, including Mounjaro, online in China. This collaboration aims to streamline consultations, prescriptions, and drug delivery, responding to the growing GLP-1 drug market, projected to reach $5.6-$11.4 billion annually. The move follows competitors like Novo Nordisk in leveraging e-commerce for sales.
Aug 29, 2025
Eli Lilly Collaborates with Chinese Technology Leader for Marketing Obesity Medication - The Business of Fashion
Eli Lilly & Co has partnered with JD Health International Inc. to sell its obesity and diabetes drug, Mounjaro, online in China. This collaboration aims to enhance access through a comprehensive service that includes consultations and prescriptions. The move reflects a shift towards e-commerce in the growing GLP-1 drug market, previously dominated by public hospitals.
Aug 29, 2025
The Impact of Rising GLP-1 Usage on Gastrointestinal Practices: Insights from Physicians - Becker's ASC
Gastroenterologists express concerns over the rising prescriptions of GLP-1 drugs, such as semaglutide (Wegovy), for obesity and metabolic diseases. While these medications offer significant benefits, they may cause gastrointestinal side effects like nausea and constipation, complicating patient care. Experts emphasize the need for long-term monitoring to address potential risks, including nutritional deficiencies and impacts on liver health.
Aug 29, 2025
Request to FDA May Delay Generic Ozempic and Impact Device-Hopping Policy
A Dubai-based law firm has petitioned the FDA to delay the approval of generic versions of Novo Nordisk's popular diabetes and weight-loss drug, Ozempic. The firm claims there are risks associated with the injector device and manufacturing processes, despite the company's unclear ties to the relevant markets.
Aug 29, 2025
ABBV or MRK: Which Stock Should Investors Consider for 2025?
Merck (MRK) and AbbVie (ABBV) are leading pharmaceutical companies with strong oncology and immunology portfolios. AbbVie’s revenue growth is driven by Skyrizi and Rinvoq, while Merck relies heavily on Keytruda. Despite challenges, AbbVie is positioned for robust growth post-Humira, while Merck faces declining sales in some areas. Both companies hold a Zacks Rank #3 (Hold).
Aug 29, 2025
Johnson & Johnson Stops Nirogacestat Study for Rheumatoid Arthritis - AInvest
Johnson & Johnson has terminated the development of its experimental antibody drug, nirogacestat, in combination with anti-TNFα therapies for rheumatoid arthritis after the DAISY study showed no significant clinical benefits. This decision impacts a project previously expected to exceed $5 billion in annual sales. The move highlights challenges in the competitive autoimmune treatment market, especially against biosimilars like AbbVie's Humira.
Aug 29, 2025
Sanofi's Shift in Strategy Towards Multi-Indication BTK Inhibitors: The Potential of Rilzabrutinib as a Major Success...
Sanofi's rilzabrutinib, marketed as Wayrilz, received FDA approval for immune thrombocytopenia (ITP) on August 29, 2025. This first-in-class BTK inhibitor demonstrated a 65% platelet response rate in trials. With four orphan drug designations, Sanofi aims to leverage its regulatory advantages and strategic partnerships to capture niche markets, projecting $242 million in U.S. revenue by 2034.
Aug 29, 2025
UPC experiences an increase in small molecule legal disputes, placing Pfizer under scrutiny in Europe.
Experts Anna Leathley, Richard Newell, and Sarah Mitchell from Carpmaels & Ransford indicate a potential increase in life sciences cases at the Unified Patent Court. However, concerns arise regarding the court's capacity to handle this anticipated uptick.
Aug 29, 2025
Catalyst Pharmaceuticals reaches a settlement in the FIRDAPSE patent dispute with Lupin. - AInvest
Catalyst Pharmaceuticals has settled patent litigation with Lupin Pharmaceuticals over FIRDAPSE (amifampridine), allowing Lupin to market a generic version starting February 2035. This agreement extends Catalyst's market exclusivity, crucial for its revenue from FIRDAPSE, which accounts for 62% of its net sales. The settlement awaits regulatory review by the U.S. Federal Trade Commission and the Department of Justice.
Aug 29, 2025
Annovis (ANVS) Obtains Patent Protection for Both Variants of Buntanetap - Yahoo Finance
Annovis Bio, Inc. (NYSE:ANVS) has secured patent protection for both semi-crystalline and crystalline forms of its drug candidate, buntanetap, extending coverage until 2046. The drug aims to treat Alzheimer’s and Parkinson’s diseases. The FDA has approved the crystalline form for a Phase 3 trial in early Alzheimer’s, currently underway at over 75 US sites.
Aug 29, 2025
A Comprehensive Analysis of Everest Medicines' Strategic Shift and Journey Towards Profitability - AInvest
Everest Medicines is showcasing a successful transformation in biopharma, achieving a 48% revenue growth in H1 2025, driven by blockbuster drugs NEFECON® and XERAVA®. The company’s dual-engine strategy emphasizes operational efficiency and R&D innovation, including advancements in AI+mRNA technology for cancer vaccines. With a focus on profitability, Everest is positioning itself as a leader in the competitive healthcare landscape.
Aug 29, 2025
Oxytocin injection discovered at pharmacy, confiscated, and samples of four medications submitted for analysis.
The FSDA team seized banned oxytocin injections during an inspection at Krishna Medical Hall in Kanpur on August 29, 2025. Samples of four other medications were also sent for testing.
Aug 29, 2025
US court permits MSN to launch a generic variant of Novartis' Entresto - Cape Argus
A federal judge in Washington, DC, denied Novartis' attempt to block MSN Pharmaceuticals from launching a generic version of Entresto, a heart-failure drug. This decision allows MSN to introduce the first US generic of the $6 billion revenue drug. Novartis is pursuing further legal action to protect its patent rights.
Aug 29, 2025
FDA-Approved Controlled Release Drug Delivery Market Size - GlobeNewswire
The global controlled release drug delivery market is projected to exceed $90 billion by 2030, driven by advancements in therapeutic applications and significant investments from major pharmaceutical companies like AbbVie, AstraZeneca, and Johnson & Johnson. Innovations include long-acting formulations for neurological disorders and the recent FDA approval of Tris Pharma's generic Delsym®. Strategic partnerships are enhancing patient access to these therapies.
Aug 28, 2025
Novo Nordisk partners with Replicate BioScience to develop new medications for obesity and diabetes.
Replicate Bioscience has partnered with Novo Nordisk to develop treatments for obesity, type 2 diabetes, and cardiometabolic diseases using self-replicating RNA technology. Novo will receive an exclusive license for Replicate's srRNA platform and provide up to $550 million in funding. This collaboration comes amid rising competition in the obesity drug market, particularly from Eli Lilly.
Aug 28, 2025
Novo's Ozempic approved in South Korea for reducing kidney risks in diabetes patients
Novo Nordisk's GLP-1 drug Ozempic (semaglutide) has received approval in South Korea for treating chronic kidney disease (CKD) in adults with type 2 diabetes. This expansion allows Ozempic to address glucose control, cardiac risk, and kidney decline, making it one of the most broadly indicated GLP-1 receptor agonists in the country. The approval is supported by the FLOW trial results.
Aug 28, 2025
XtalPi's drug revenue surge of 615% underscores the growth of China's biotech sector following the DoveTree agreement.
XtalPi, a Shenzhen-based biotech firm, reported a 615% increase in first-half revenue from its drug-discovery business, reaching 435 million yuan (US$61 million), driven by a US$6 billion deal with US-based DoveTree. The company’s net profit surged to 141.6 million yuan, reversing a previous loss, as it capitalizes on AI and robotics in drug development.
Aug 28, 2025
Promising developments in precision cancer medications from Kelun-Biotech - Insights for global investors in the Chinese stock market.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. reported a 31.3% revenue drop to 950 million yuan in H1 2025, yet its share price soared to a record high. The rise is attributed to strong sales of its breast cancer drug, sacituzumab tirumotecan, which reached 302 million yuan. The company aims for national insurance coverage for its products, potentially boosting future earnings.
Aug 28, 2025
iNtRON Bio Submits Two Patents for Innovative IMPA™ Gene Editing Technology - SynBioBeta
iNtRON Bio has completed two patent filings for its novel IMPA™ gene editing technology, which utilizes CRISPR-Cas9 to target Pasteurella bacteriophages. This foundational technology aims to enhance genetic engineering applications, including anticancer drugs and vaccines. CEO YOON, Kyung Won emphasized the technology's potential for broad pharmaceutical use, while the company plans to expand its applications beyond Pasteurella.
Aug 28, 2025
Counterfeit drugs valued at Rs 2.13 crore seized from Himanshu Agarwal's storage facility, investigation ongoing...
Authorities in Agra have recovered fake medicines valued at Rs 2.13 crore from a warehouse owned by Himanshu Agarwal. The Food Safety and Drug Administration (FSDA) and Special Task Force (STF) are actively investigating the drug market, leading to the registration of another case in connection with this operation.
Aug 28, 2025
India grants approval for Zolgensma, among the most expensive medications globally. Here's why it has generated both optimism and apprehension.
A mother in Maharashtra is raising funds for Zolgensma, a gene therapy by Novartis, to treat her five-month-old daughter with Spinal Muscular Atrophy (SMA). The therapy, priced at Rs 17.7 crore in the US, offers hope for survival if administered early. The Central Drugs Standard Control Organisation has approved Zolgensma for commercial launch in India, potentially reducing costs.
Aug 28, 2025
Sandoz's Strategic Growth in Generic Anticoagulants and Its Impact on the Development of Biosimilars
Sandoz, a Novartis subsidiary, is successfully expanding into generic anticoagulants and biosimilars, notably with its generic rivaroxaban following a patent victory over Bayer. The company’s biosimilars, including denosumab products, are driving significant sales growth, accounting for 29% of net sales in H1 2025. Sandoz's strategic legal and regulatory maneuvers position it as a leader in the $300 billion biosimilars market.
Aug 28, 2025
Oncotelic's CEO Secures Patents Resulting in $4.2 Billion in Biotech Acquisitions | OTLC Stock Update
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) showcased its extensive oncology and immunotherapy pipeline, led by CEO Dr. Vuong Trieu, who holds over 500 patents. Key assets include OT-101 for pancreatic cancer and OXi4503 for AML/MDS. The company aims to address high unmet medical needs while leveraging Dr. Trieu's innovations to develop life-saving therapies.
Aug 28, 2025
Oncotelic Therapeutics Highlights Strong Development Pipeline and Founder's Extensive Intellectual Property Portfolio
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) highlights its oncology and immunotherapy pipeline, led by CEO Dr. Vuong Trieu, who has over 500 patents. Key assets include OT-101 for pancreatic cancer and OXi4503 for AML/MDS. The company aims to address unmet medical needs with innovative therapies while leveraging Dr. Trieu's extensive intellectual property portfolio.
Aug 28, 2025
Anthem Biosciences informs Delhi High Court that it will not introduce products containing the anti-cancer medication Alectinib.
Justice Tejas Karia has issued a notice to Anthem Biosciences in a patent infringement case filed by Chugai Pharmaceutical. The court has recorded an undertaking from Anthem not to launch any products related to Alectinib or its derivatives until the next hearing on October 9.
Aug 27, 2025
European Commission Greenlights Gilead's Biannual Injectable PrEP for HIV Prevention
The European Commission has approved Gilead Sciences' long-acting injectable treatment for HIV pre-exposure prophylaxis (PrEP), making it the first twice-yearly option in the EU. This innovative treatment offers a convenient alternative to daily oral medications, enhancing accessibility for individuals seeking HIV prevention. The approval follows a comprehensive evaluation of its efficacy and safety.
Aug 27, 2025
MSN Requests Supreme Court Examination in Novartis Patent Dispute - Bloomberg Law News
MSN Pharmaceuticals Inc. has appealed to the US Supreme Court to overturn Federal Circuit rulings that it claims grant excessive protection to broad drug patents, specifically targeting a Novartis Pharmaceuticals Corp. patent for the heart failure drug Entresto, which combines valsartan and sacubitril. MSN argues the patent's claims are overly broad and should be deemed invalid.
Aug 27, 2025
Amylyx's previous ALS medication does not succeed in treating another neurological condition, shifting attention to GLP-1.
Aug 27, 2025
Could Camzyos Enhance BMY's Cardiovascular Offerings? - TradingView
Bristol Myers Squibb (BMY) reported strong sales for its cardiovascular drugs, with Eliquis generating $3.7 billion in Q2, up 6%, and Camzyos achieving $260 million, surging 86%. However, Eliquis faces generic competition later this decade. BMY's pipeline includes milvexian, with expected readouts next year. Competition from Cytokinetics' aficamten and Johnson & Johnson's Xarelto is also anticipated.
Aug 27, 2025
Novo Nordisk or Viking Therapeutics: Which GLP-1 Stock Offers More Stability? - TradingView
Novo Nordisk (NVO) and Viking Therapeutics (VKTX) are key players in the obesity treatment market, with NVO's semaglutide drugs like Wegovy facing competition from Eli Lilly's Mounjaro and Zepbound. VKTX's VK2735 shows promise but faces challenges after mixed study results. Both companies have bearish ratings, with NVO struggling with market share and VKTX lacking an approved product.
Aug 27, 2025
AbbVie Rises 16.6% Year-to-Date Following Five Months of Declining Prices - AInvest
AbbVie Inc. (ABBV) reported a strong August with an 11.4% monthly gain and a 16.6% year-to-date increase, rebounding from earlier price weakness. Key drugs like Rinvoq and Skyrizi contributed to a 12.1% rise in earnings per share. The company’s successful navigation of the Humira patent cliff and ongoing acquisitions bolster its growth prospects.
Aug 27, 2025
Federal Court of Appeal rules that generic manufacturers are not obligated to respond to patents filed prior to...
On August 8, 2025, the Federal Court of Appeal upheld the Minister of Health's decision to list Canadian Patent No. 2,970,315 on the Patent Register after confirming its eligibility. Bayer Inc argued against the decision, claiming it created an unfair race with Amgen Canada Inc, but the FCA found the Minister's interpretation reasonable. Bayer may seek to appeal to the Supreme Court of Canada.
Aug 27, 2025
Trends and Global Projections for the Nanoparticle Formulation Market Through 2035 - GlobeNewswire
The global nanoparticle formulation market is projected to grow from USD 5.1 billion in 2025 to USD 15.1 billion by 2035, at a CAGR of 9.4%. The report highlights over 100 nanoparticle technologies, with a focus on organic nanoparticles for drug delivery, particularly in oncology. Key players include Ascension Sciences, DIANT Pharma, and Nanoform.
Aug 27, 2025
Implementing Price Controls Will Not Solve the Issue of Rising Drug Prices - City Journal
The U.S. drug-price debate intensifies as President Trump’s May 12 executive order proposes most-favored-nation pricing to align U.S. drug costs with lower prices in developed countries. Critics argue this could raise costs and disrupt innovation. Pfizer CEO Albert Bourla suggests a NATO-like alliance for fairer cost-sharing. The administration faces legal and practical challenges in enforcing these price controls.
Aug 27, 2025
Catalyst Pharmaceuticals Settles Patent Dispute Over FIRDAPSE with Lupin ... - AInvest
Catalyst Pharmaceuticals has settled patent litigation with Lupin Pharmaceuticals, permitting Lupin to market a generic version of FIRDAPSE (amifampridine) in the U.S. no earlier than February 25, 2035. This agreement resolves ongoing litigation and extends Catalyst's market exclusivity for FIRDAPSE, crucial for its revenue, while also undergoing regulatory review by the U.S. Federal Trade Commission and Department of Justice.
Aug 27, 2025
Cartherics receives patent in China for improving immune cell performance.
Cartherics has received a patent from the Chinese Patent Office for a method enhancing immune cell function by knocking out the adenosine A2A receptor in induced pluripotent stem cells. This innovation aims to improve natural killer cell activity against solid tumors, particularly in ovarian cancer and endometriosis, bolstering the company's position in women's health therapies.
Aug 26, 2025
Moody's predicts that the swift expansion of weight-loss medications will impact various industries in the years ahead.
The rapid growth of weight-loss drugs, including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly, is set to influence various sectors, with projected annual sales reaching $80 billion by 2030. Experts discuss the implications for the pharmaceutical industry and related sectors like packaged food and restaurants.
Aug 26, 2025
Analysis: The Potential Dangers of Data Exclusivity in the Pharmaceutical Industry - The Financial Express
Commerce Minister Piyush Goyal's push for data exclusivity in India's pharmaceutical sector could hinder the entry of generic medicines, according to KM Gopakumar. This policy, aimed at attracting R&D investments, may facilitate evergreening and compromise affordable drug access. The Patents Act reforms, influenced by FTAs with the USA and EU, risk prioritizing IP holders over public health.
Aug 26, 2025
Press Announcement: Senators Hassan and Hawley Unveil Collaborative Legislation to Tackle Patent Issues...
U.S. Senators Maggie Hassan and Josh Hawley have introduced the bipartisan Medication Affordability and Patent Integrity Act to combat patent abuses by drug manufacturers and lower prescription costs. The legislation aims to enhance collaboration between the FDA and USPTO, preventing pharmaceutical companies from exploiting patent loopholes to delay access to affordable medications.
Aug 26, 2025
Senators Hassan and Hawley Unveil Joint Bill Aimed at Addressing Big Pharma's...
U.S. Senators Maggie Hassan and Josh Hawley have introduced the Medication Affordability and Patent Integrity Act to reduce prescription drug costs by closing loopholes that allow drug manufacturers to extend exclusivity periods unfairly. The legislation aims to enhance coordination between the FDA and USPTO, ensuring transparency and fostering competition, ultimately lowering prices for patients.
Aug 26, 2025
iNtRON Bio submits two patent applications for its gene editing technology based on the IMPA™ platform.
iNtRON Bio has filed two new patents for its IMPA™ gene editing technology, utilizing CRISPR-Cas9 to target Pasteurella bacteriophages. This advancement allows for precise genetic manipulation and the incorporation of diverse payloads, enhancing the potential for developing targeted therapeutics and vaccines. The technology aims to broaden applications in the pharmaceutical industry, including anticancer drugs.
Aug 26, 2025
Delhi High Court criticizes Gautam Gambhir Foundation over Covid medication distribution issue.
The Delhi High Court has criticized the Gautam Gambhir Foundation for 'name-dropping' in a case related to the distribution of Covid drugs. The court declined to halt criminal proceedings against the foundation and its members, including Indian cricket team head coach Gautam Gambhir.
Aug 26, 2025
Pharmaceutical Companies Seek Collaborations to Tackle Patent Expirations as Interest in In Vivo Research Grows
Pharmaceutical firms are increasingly forming partnerships to navigate patent cliffs and rising tariff challenges, according to a recent analysis. The report highlights the shift towards in vivo cell therapy, which delivers genetic material directly to patients, as companies seek innovative solutions to maintain profitability amid expiring patents and intensified generic competition.
Aug 26, 2025
HCW Biologics Shares Experience Largest Increase Since May Following Cancer Treatment Advancement
HCW Biologics (HCWB) shares surged 60.8% after announcing promising results for its next-generation version of pembrolizumab, sold as Keytruda by Merck. The new therapy aims to enhance immune response against cancer and may also target age-related diseases. Early studies show stronger efficacy than Keytruda, raising hopes for a multi-billion-dollar market potential.
Aug 26, 2025
Gilead's Yeytuo receives EU approval, enhancing its potential as a top-selling drug.
The European Commission has approved Gilead's Yeytuo (lenacapavir) for HIV prevention, following its US approval in June 2024. This injectable drug, administered biannually, shows high efficacy in preventing HIV-1 infections. Analysts and health organizations hail it as a breakthrough in HIV prevention, although cost may hinder global uptake. Gilead plans further regulatory reviews in multiple countries.
Aug 26, 2025
Gyre Therapeutics: An Attractive Investment Opportunity with Promising Drug Hydronidone
Gyre Therapeutics (GYRE) has received a Buy rating from H.C. Wainwright analyst Matthew Keller, who highlights the potential of its lead asset, hydronidone, a fibrosis inhibitor. With promising late-stage trial results for chronic hepatitis-B liver fibrosis, hydronidone is expected to enter Phase 2 trials in the U.S. by 2025, with projected annual sales of $6 billion by 2033.
Aug 26, 2025
Eli Lilly's daily weight loss medication achieves success in recent trials, clearing the path for worldwide authorization.
Eli Lilly's once-daily weight loss pill, orforglipron, has shown effectiveness in a key trial for individuals with obesity and type 2 diabetes, paving the way for global regulatory approval. Patients lost an average of 10.5% of their weight after 72 weeks. Lilly plans to seek approval by the end of 2025, aiming to redefine obesity treatment.
Aug 25, 2025
Xeris Reveals Inclusion of U.S. Patent for Recorlev® in the Orange Book - The Globe and Mail
Xeris Biopharma Holdings, Inc. announced the issuance of U.S. Patent 12,377,096 for Recorlev® (levoketoconazole), enhancing its intellectual property protection. This patent, listed in the FDA's Orange Book, covers methods to treat diseases while minimizing drug interactions and extends to March 2040. Recorlev is approved for treating endogenous Cushing’s syndrome in patients for whom surgery is not an option.
Aug 25, 2025
Protecting Intellectual Property: Patent Approaches for Drug Repurposing Enhanced by AI - Mondaq
A recent review by Wan et al. in Advanced Science highlights the potential of artificial intelligence (AI) to accelerate drug repurposing, addressing challenges like clinical efficacy and regulatory hurdles. AI can analyze vast datasets to identify new therapeutic uses for existing drugs, transforming the process into a systematic approach. However, repurposed drugs face patent protection challenges that require strategic solutions.
Aug 25, 2025
An Overview of the Semaglutide Patent Environment - Mondaq
Novo Nordisk's semaglutide, featured in its weight-loss drugs Ozempic® and Wegovy®, has driven global anti-obesity medication spending to over $30 billion in 2024. Despite its success, Novo Nordisk faces patent challenges, including a recent European Patent Office ruling that revoked a patent for lack of inventive step, highlighting the competitive landscape in obesity treatment.
Aug 25, 2025
Xeris Biopharma Reveals Recorlev Patent Listed in the Orange Book - AInvest
Xeris Biopharma Holdings has received a patent for Recorlev® (levoketoconazole) from the U.S. Patent and Trademark Office, now listed in the FDA's Orange Book. The patent, valid until March 2040, covers methods for treating diseases while minimizing drug interactions. Recorlev is approved for adult patients with endogenous Cushing's syndrome when surgery is not viable.
Aug 25, 2025
Celltrion has revealed its plan to transform into a "global new drug pharmaceutical company...
Celltrion has announced its new drug development strategy, focusing on antibody-drug conjugates (ADCs) for gastroesophageal cancer treatment. The company aims to enter Phase 1 trials for three ADCs (CT-P70, CT-P71, CT-P73) this year, with CT-P70 targeting FDA approval by 2030. Celltrion plans to develop dual antibody and dual payload ADCs to enhance treatment efficacy.
Aug 25, 2025
Serena Williams' support for a weight-loss medication: Beneficial for pharmaceutical companies, detrimental for patients.
Serena Williams, now a brand ambassador for a healthcare company promoting weight-loss drugs, faces criticism for endorsing a potentially harmful message about body image. Her promotion of these FDA-approved drugs raises concerns about normalizing their use without medical supervision. Critics argue that this could undermine personal health efforts and encourage reliance on medication over lifestyle changes.
Aug 25, 2025
Despite having access to popular obesity medications, certain individuals still struggle to shed pounds - Yahoo
Danielle Griffin, a 38-year-old from New Mexico, accessed the weight-loss drugs Ozempic and Wegovy without issue, but found them ineffective for her. Experts warn that up to 20% of patients may be "nonresponders," losing less than 5% of body weight, highlighting the variability in effectiveness of these popular obesity treatments.
Aug 25, 2025
Cohance Lifesciences Stock Attracts Attention as Jefferies Begins Coverage with a 'Buy' Recommendation
Cohance Lifescience shares are set to attract attention on August 25, as Jefferies initiated coverage with a 'Buy' rating and a target of Rs 1,150. The firm highlighted Cohance's strong positioning in the Antibody Drug Conjugate segment and projected a 20% sales CAGR through FY25-28E, with potential sales of $26 billion by 2030.
Aug 25, 2025
New Treatment for Uncommon Tumor Shows Great Promise, But Is Precigen Financially Prepared?
The FDA has approved Precigen's immunotherapy, Papzimeos, as the first drug treatment for recurrent respiratory papillomatosis (RRP), caused by HPV6 and HPV11. Despite its potential as a blockbuster, Precigen faces financial challenges, with only $59.7 million in cash. Competitor Inovio is also developing a treatment, INO-3107, which may enter the market soon.
Aug 24, 2025
Smuggler apprehended with 6,600 capsules of Pregabalin, according to DrugsControl Media Services.
Police in Sri Ganganagar arrested a smuggler with 6,600 Pregabalin capsules during a special anti-drug operation. The arrest was part of a broader campaign against narcotics in the Bikaner range. Authorities are currently interrogating the suspect regarding the origin and distribution of the seized drugs.
Aug 24, 2025
Counterfeit medications valued in crores seized in Agra - Drugs Control Media Services
Authorities in Agra have uncovered a major counterfeit medicine operation, recovering fake drugs valued at approximately Rs 1 crore. The operation, conducted by the FSDA and local police, revealed a network linked to Chennai. Investigations are ongoing to dismantle the racket and prevent further distribution of these illicit products.
